

NEUROLOGIC COMPLICATIONS ASSOCIATED WITH H1N1 INFLUENZA IN THE PEDIATRIC POPULATION

Siresha Chaluvadi, M.D^a; Satish Agadi, MD^{a, b}; James J Riviello, MD^{a, b}

^a Department of Neurology, Baylor College of Medicine, Houston, Texas,

^b Department of Pediatrics, Division of Neurology, Texas Children's Hospital, Houston, Texas



Rationale

The numbers of hospitalizations, multiorgan complications, and deaths continued to rise during the H1N1 influenza pandemic. Although there are several reports of H1N1 influenza associated neurologic complications in all ages, there is no clear suggestion that the 2009 influenza A (H1N1) virus is associated with a disproportionate amount of neurologic illness beyond that observed with seasonal influenza.

We describe the serious neurologic complications of children hospitalized with H1N1 influenza in Houston, Texas during the 2009 season. We retrospectively studied five hospitalized children with neurological complications who were polymerase chain reaction (PCR) positive for the H1N1 virus (PICU).

Case Reports

Pt	Age/gender	Admit Chief Complaint	PCR + for H1N1	Cranial MRI	MRA/MRV	EEG	CSF	CNS complications	Outcome
1	6 yo/F	RD, T 104	yes	L MCA stroke, R BG ICH	4 vessel - vasculitis	decreased amplitude of the left centroparietal area and diffuse slowing	ND	stroke (ischemic and hemorrhagic)	Improved overall, residual R hemiparesis
2	10 month/M	RD, T 102	yes	R BG infarct	Normal	diffuse slowing increased slowing in L occipital region	no WBCs, RBCs, or organisms protein 18, glucose 71, opening pressure 31 mg H2O	stroke (ischemic)	Improved
3	10 yo/F	Hematuria	yes	Patchy hyperdensities of frontal lobe	ND	generalized epileptiform discharges and diffuse slowing with possible focal slowing	protein 61, all else was normal	encephalopathy, seizures (Partial seizures with secondary generalization)	Improved
4	6 yo/M	RD	yes	ND	ND	asymmetric focal slowing in the temporal region	NA	encephalopathy	Death
5	6 yo/M	New onset Seizures	yes	WNL	WNL	focal slowing in the right temporo-parietal regions	WBC1, RBC 0, total protein 13, glucose 95	encephalopathy, status epilepticus	Improved

Results

Of these 5 children, 2 had stroke (ischemic and/or hemorrhagic), 2 had seizures, and 3 had encephalopathic features. Regarding the outcome, improvement in neurological function occurred in four and one child died.

Among all H1N1 influenza PCR positive patients admitted to the PICU that month, 21% had neurologic complications.

Conclusion

There are several case reports of neurologic complications with H1N1 influenza infection in children and in adults^{1,2}. The severity of the neurologic disease in the five children described in this report included a wider range of symptoms and complications than those described in prior case reports²⁻⁴. In the previous case reports related to H1N1 influenza neurological complications, the manifestations were generally mild and included mainly new onset seizures²⁻⁴.

Our patients had a different clinical profile. Two out of 5 children had stroke (hemorrhagic or ischemic), 2 of the 5 children had seizures, and 3 children had severe encephalopathic features. The variability of CNS complications in this group stresses the importance of recognizing the CNS complications of H1N1 influenza in endemic areas. Clinicians should consider H1N1 influenza associated encephalopathy in the differential diagnosis of children with influenza-like illness with seizures, stroke-like manifestations, or mental status changes and remain aware of the potential for severe neurologic sequelae associated with the novel influenza A (H1N1) virus infection.

The Centers for Disease Control (CDC) recommends that vaccinations should be given to pregnant women, those persons who live with or provide care for infants aged less than 6 months, health-care and emergency medical services personnel who have direct contact with patients or infectious material, children aged 6 months to 4 years, and children and adolescents aged 5 to 18 years who have medical conditions that put them at higher risk for influenza-related complications. Following these strict guidelines is imperative to those clinicians treating these vulnerable populations.

References

1. Baltagi SA, et al. *Pediatr Crit Care Med* 2010; 11 (2): 1-3
2. Tan K, Prerna A, Leo YS. *Lancet Neurol* 2010; 9 (2): 142-3.
3. Cox N, Subbarao K. *Lancet*. 1999; 354: 1277-1282.
4. Morishima T, et al. *Clin Infect Dis*. 2002; 35: 512-517.